Clinical trial of ethanolamine oleate sclerotherapy for hemangioma in the oral and maxillofacial region

Clinical trial of ethanolamine oleate sclerotherapy for hemangioma in the oral and maxillofacial region - Clinical trial of ethanolamine oleate sclerotherapy for hemangioma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002558

Enrollment

Registered

2009-10-01

Start date

2009-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

low flow hemangioma of oral and maxillofacial region

Interventions

We measure the blood flow in the tumor with CT using contrast medium. If the tumor ia low flow, we inject 5% ethanolamine oleate and watch for 5 minutes. After that, we collect the sclerosing agent.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient who has low flow hemangioma Patient who accept the participation in this trial

Exclusion criteria

Exclusion criteria: Patient who has kidney trouble (24h CCr<= 70L/day) Patient who is unsuitable to this trial

Design outcomes

Primary

Measure	Time frame
Improvement of tumor size in clinical findings or MRI remarks. Recurrence rate at 1 year after treatment	—

Secondary

Measure	Time frame
Incidences of complications or side effects	—

Countries

Japan

Contacts

Public ContactAtsushi Danjo

Saga University Hospital Oral and maxillofacial Surgery

danjoat@cc.saga-u.ac.jp0952-34-2397

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026